Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-16.30 Insider Own33.10% Shs Outstand21.15M Perf Week1.04%
Market Cap4.67B Forward P/E- EPS next Y-5.68 Insider Trans28.13% Shs Float14.16M Perf Month-12.87%
Income-315.20M PEG- EPS next Q-0.12 Inst Own57.90% Short Float5.69% Perf Quarter-15.05%
Sales1.60M P/S2921.34 EPS this Y48.90% Inst Trans-1.54% Short Ratio1.70 Perf Half Y-25.15%
Book/sh-7.88 P/B- EPS next Y61.70% ROA-205.10% Target Price454.45 Perf Year380.43%
Cash/sh6.34 P/C34.86 EPS next 5Y-4.07% ROE-927.40% 52W Range42.41 - 497.00 Perf YTD223.67%
Dividend- P/FCF- EPS past 5Y0.00% ROI-47.90% 52W High-55.53% Beta-
Dividend %- Quick Ratio0.50 Sales past 5Y- Gross Margin- 52W Low421.10% ATR11.07
Employees50 Current Ratio0.50 Sales Q/Q0.00% Oper. Margin- RSI (14)43.59 Volatility3.23% 4.60%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.43 Prev Close227.49
ShortableYes LT Debt/Eq- EarningsAug 11 Payout- Avg Volume473.78K Price221.00
Recom1.90 SMA20-3.59% SMA50-10.89% SMA200-0.44% Volume201,590 Change-2.85%
01-Jul-14Initiated RBC Capital Mkts Outperform $425
15-May-14Initiated Summer Street Research Buy $650
08-May-14Reiterated Oppenheimer Outperform $525 → $499
18-Mar-14Reiterated Needham Buy $320 → $500
14-Mar-14Reiterated Oppenheimer Outperform $360 → $525
10-Jan-14Reiterated Oppenheimer Outperform $94 → $360
10-Jan-14Reiterated Needham Buy $55 → $320
01-Oct-13Reiterated Oppenheimer Outperform $64 → $94
13-Aug-13Reiterated Needham Buy $40 → $55
11-Jul-13Reiterated Oppenheimer Outperform $60 → $64
16-Jan-13Reiterated Wedbush Outperform $25 → $46
04-Jan-13Reiterated Needham Buy $24 → $40
05-Nov-12Initiated Needham Buy $24
24-Jul-14 10:00AM  Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic Accesswire
23-Jul-14 03:31PM  Puma Biotechnology: Another Jackpot For Investors at Forbes
11:45AM  Puma Pumps up Biotech ETFs ETF Trends
22-Jul-14 05:01PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events EDGAR Online
15-Jul-14 01:40PM  [video] Next global epidemic? at CNBC
08:06AM  This liver disease could rival hepatitis C at CNBC
08:06AM  Market for this liver drug could rival hepatitis C at CNBC
14-Jul-14 11:51AM  Intercept Pharmaceutical Shares Up Amid Deutsche Bank Initiation Benzinga
11:47AM  Intercept Pharmaceuticals: 'Good Risk/Reward,' Deutsche Bank Says at Barrons.com
08-Jul-14 08:01AM  Halozyme Attracting Attention With Upcoming Adcom And Potential Blockbuster Pancreatic Cancer Treatment at Seeking Alpha -6.11%
03-Jul-14 12:42PM  Could Galectin Therapeutics Stock Be Your Next Home Run? at Motley Fool
01-Jul-14 11:29AM  Biotech: Buy the Trial, Sell the Approval? at Barrons.com
06:33AM  Coverage initiated on Intercept Pharma by RBC Capital Mkts Briefing.com
29-Jun-14 01:36PM  5 of Last Week's Biggest Losers at Motley Fool
09:00AM  3 Stocks Crushed by the Market This Week at Motley Fool
27-Jun-14 05:00PM  Are Investors Wrong About Raptor Pharmaceuticals? at Motley Fool
05:00PM  Are Investors Wrong About Raptor Pharmaceuticals?
26-Jun-14 07:12PM  Intercept Pharmaceuticals' Drop Proves How Impatient Investors Are at Motley Fool -5.61%
07:12PM  Intercept Pharmaceuticals' Drop Proves How Impatient Investors Are
12:18PM  Analysts Comment On Intercept Pharmaceuticals Amid Share Decline Following FLINT Data Delay Benzinga
12:18PM  Analysts Comment On Intercept Pharmaceuticals Amid Share Decline Following FLINT Data Delay
12:18PM  Analysts Comment On Intercept Amid Share Decline Following FLINT Data Delay
09:40AM  Catalysts on the Horizon for Companies Developing NAFLD and NASH Drugs Accesswire
09:40AM  Catalysts on the Horizon for Companies Developing NAFLD and NASH Drugs
09:03AM  Intercept thesis unchanged with pushed out data, says Summer Street at theflyonthewall.com
09:03AM  Intercept thesis unchanged with pushed out data, says Summer Street
25-Jun-14 05:37PM  [video] Stock Pops & Drops: DDD, AGN, ICPT, ZU at CNBC -7.30%
05:37PM  [video] Stock Pops & Drops: DDD, AGN, ICPT, ZU
10:50AM  Intercept says FLINT data 'unlikely' to come in July at theflyonthewall.com
10:50AM  Intercept says FLINT data 'unlikely' to come in July
10:28AM  Intercept drops 4% during conference presentation theflyonthewall.com
10:28AM  Intercept drops 4% during conference presentation
09-Jun-14 08:06PM  Why Family Dollar, International Game Technology, and Intercept Phamaceuticals Jumped Today at Motley Fool +6.89%
12:09PM  Why These Two Biotech ETFs Are Soaring Monday ETF Trends
12:09PM  Why These Two Biotech ETFs Are Soaring Monday
06-Jun-14 08:05AM  Intercept to Present at Upcoming Investor Conferences GlobeNewswire
08:05AM  Intercept to Present at Upcoming Investor Conferences
04-Jun-14 06:02PM  Nasdaq stocks posting largest percentage increases AP +11.28%
29-May-14 10:50AM  Intercept's Obeticholic Acid Gets Fast Track Status Zacks
10:50AM  Intercept's Obeticholic Acid Gets Fast Track Status
10:18AM  Intercept Pharmaceuticals: Another Double? at Barrons.com
10:18AM  Intercept Pharmaceuticals: Another Double?
08:36AM  Today's Top Biotech Stocks to Watch: Intercept Pharmaceuticals and VIVUS at Motley Fool
08:36AM  Today's Top Biotech Stocks to Watch: Intercept Pharmaceuticals and VIVUS
08:35AM  Morning Movers: Intercept Pharma Flies on FDA Fast Track; Tilly's Tanks at Barrons.com
08:35AM  Morning Movers: Intercept Pharma Flies on FDA Fast Track; Tilly's Tanks
28-May-14 06:58PM  On The Fly: After Hours Movers at theflyonthewall.com
05:00PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events EDGAR Online
05:00PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events
04:18PM  Intercept gets FDA fast track designation to obeticholic acid at theflyonthewall.com
04:18PM  Intercept gets FDA fast track designation to obeticholic acid
04:15PM  Intercept Announces that FDA Grants Fast Track Designation to Obeticholic Acid for the Treatment of Patients with Primary Biliary Cirrhosis GlobeNewswire
04:15PM  Intercept Announces that FDA Grants Fast Track Designation to Obeticholic Acid for the Treatment of Patients with Primary Biliary Cirrhosis
09:36AM  3 Stocks Crushed by the Market Last Week at Motley Fool
09:36AM  3 Stocks Crushed by the Market Last Week
06:14AM  Intercept sell-off on email disclosures overdone, says Citigroup at theflyonthewall.com
22-May-14 06:07AM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online +6.19%
12:14AM  [$$] Intercept Pharmaceuticals Didn't Disclose Cholesterol Data at The Wall Street Journal
21-May-14 10:50PM  [$$] Intercept Pharmaceuticals Didn't Disclose Cholesterol Data at The Wall Street Journal
08:26PM  [$$] Intercept Didn't Disclose Cholesterol Data at The Wall Street Journal
07:49PM  [$$] Intercept Didn't Disclose Cholesterol Data at The Wall Street Journal
05:00PM  Intercept Sinks on Cholesterol Issue Zacks
12:10PM  [$$] Seize an Opportunity in Intercept Pharma at Barrons.com
11:40AM  Intercept Pharmaceuticals: Much Ado About Nothing? at Barrons.com
07:40AM  Intercept conduct wasn't nefarious, says Oppenheimer at theflyonthewall.com
07:31AM  [$$] Seize an Opportunity in Intercept Pharma at Barrons.com
20-May-14 04:27PM  On The Fly: Closing Wrap at theflyonthewall.com -14.10%
11:53AM  Intercept pullback a buying opportunity, says Wedbush at theflyonthewall.com
10:27AM  Intercept drops following report that information was withheld at theflyonthewall.com
08:32AM  Intercept disclosure timing seems 'somewhat irrelevant,' says Summer Street at theflyonthewall.com
06:14AM  Intercept knew of abnormal cholesterol levels, The Street reports at theflyonthewall.com
06:00AM  Intercept Pharma, Government Scientists Spar Over Negative Safety of Liver Drug, Emails Show at TheStreet
19-May-14 07:20AM  Intercept data should be positive catalyst for shares, says Oppenheimer at theflyonthewall.com -7.23%
16-May-14 01:04PM  INTERCEPT PHARMACEUTICALS INC Financials EDGAR Online Financials
15-May-14 10:04AM  Intercept rises after analyst targets shares to more than double at theflyonthewall.com
08:40AM  Intercept volatility at historic lows at theflyonthewall.com
08:32AM  Coverage initiated on Intercept Pharma by Summer Street Research Briefing.com
08:17AM  Intercept initiated with a Buy at Summer Street at theflyonthewall.com
14-May-14 05:34PM  Here's What This $8 Billion Contrarian Has Been Buying at Motley Fool
13-May-14 11:40AM  What Biotech Investors Need to Know About Phase 2 Trials at Motley Fool
10:20AM  Wall Street In and Out of Love with NASH Drug Developers Accesswire
09-May-14 05:16PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
08-May-14 08:36PM  Why Tesla Motors, Dendreon, and Intercept Pharmaceuticals Tumbled Today at Motley Fool -9.13%
07-May-14 10:49PM  Intercept Pharmaceuticals' (ICPT) CEO Mark Pruzanski on Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
04:19PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations a EDGAR Online
04:05PM  Intercept Pharmaceuticals Reports First Quarter 2014 Financial Results GlobeNewswire
07:07AM  Q1 2014 Intercept Pharmaceuticals Inc Earnings Release - After Market Close CCBN
06-May-14 04:05PM  Intercept Reports Additional Positive OCA Data in Patients With Bile Acid Diarrhea at Digestive Disease Week GlobeNewswire
01-May-14 06:05AM  Intercept to Host First Quarter 2014 Update on May 7 and Present at Upcoming Investor Conferences GlobeNewswire
29-Apr-14 06:34PM  Intercept Pharmaceuticals: What Investors Need to Watch at Motley Fool
25-Apr-14 11:43AM  Commit To Purchase Intercept Pharmaceuticals At $150, Earn 28.7% Using Options at TheStreet
22-Apr-14 06:02PM  Nasdaq stocks posting largest percentage increases AP +16.79%
01:19PM  Nasdaq stocks posting largest percentage increases AP
21-Apr-14 07:40PM  The Biggest Biotech Wins of the Week at Motley Fool
18-Apr-14 10:00PM  INTERCEPT 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. - ICPT Marketwired
17-Apr-14 04:31PM  INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
14-Apr-14 04:41PM  Intercept Pharmaceuticals Larger Than S&P 500 Component PerkinElmer at TheStreet
03:30PM  Positive Results on Intercept Pharma's OCA Zacks
10:54AM  Weekly CFO Sells Highlight: Intercept Pharmaceuticals Inc., Micron Technology Inc., Facebook Inc. Gurufocus
07:31AM  Intercept Pharmaceuticals (Part IIa) - Quick Takeaways On OCA From EASL Abstracts And Presentations at Seeking Alpha
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trial to treat portal hypertension; in Phase II clinical trial for the treatment of alcoholic hepatitis; in Phase IIb clinical trial for the treatment of nonalcoholic steatohepatitis; and in Phase IIa clinical trial to treat bile acid diarrhea. The company was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VEITINGER KLAUS R DRDirectorJul 10Option Exercise21.503918,4072,171Jul 11 09:00 PM
VEITINGER KLAUS R DRDirectorJul 10Sale219.1539185,6881,780Jul 11 09:00 PM
TALLARIGO LORENZODirectorJul 07Option Exercise9.822,00019,6452,000Jul 09 09:00 PM
TALLARIGO LORENZODirectorJul 07Sale243.062,000486,1100Jul 09 09:00 PM
Regan Daniel PaulChief Commercial OfficerJul 03Option Exercise37.691381,411Jul 08 09:00 PM
Regan Daniel PaulChief Commercial OfficerJul 03Sale250.0012501,410Jul 08 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentJul 02Sale247.65849210,25715,027Jul 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentJul 01Option Exercise10.404,00041,60020,063Jul 03 09:01 PM
Pruzanski MarkCEO & PresidentJul 01Option Exercise8.6710,00086,667485,042Jul 03 09:01 PM
Pruzanski MarkCEO & PresidentJul 01Sale250.6110,0002,506,121475,042Jul 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentJul 01Sale244.144,1871,022,19515,876Jul 03 09:01 PM
Pruzanski MarkCEO & PresidentJun 02Option Exercise8.6710,00086,667480,174Jun 04 09:00 PM
Pruzanski MarkCEO & PresidentJun 02Sale230.6010,0002,305,993470,174Jun 04 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMay 15Option Exercise10.404,00041,60019,183May 19 09:00 PM
Fundaro PaoloDirectorMay 15Option Exercise9.826,92267,9908,577May 19 09:02 PM
Shapiro DavidCMO and EVP - DevelopmentMay 15Sale276.034,7431,309,20014,440May 19 09:00 PM
Fundaro PaoloDirectorMay 09Sale232.0032575,4001,655May 09 09:03 PM
VEITINGER KLAUS R DRDirectorMay 09Sale230.9516237,4141,780May 09 09:02 PM
TALLARIGO LORENZODirectorMay 09Sale232.0036785,1440May 09 09:01 PM
Adorini LucianoChief Scientific OfficerMay 07Option Exercise10.402,00020,8009,464May 09 09:00 PM
TALLARIGO LORENZODirectorMay 07Sale259.761,640426,0080May 09 09:01 PM
Adorini LucianoChief Scientific OfficerMay 07Sale259.442,000518,8757,464May 09 09:00 PM
VEITINGER KLAUS R DRDirectorMay 07Sale254.36665169,1501,617May 09 09:02 PM
Pruzanski MarkCEO & PresidentMay 01Option Exercise8.6710,00086,667480,174May 02 09:02 PM
Pruzanski MarkCEO & PresidentMay 01Sale263.1710,0002,631,661470,174May 02 09:02 PM
Pruzanski MarkCEO & PresidentApr 16Option Exercise8.6710,00086,667480,174Apr 17 09:00 PM
Pruzanski MarkCEO & PresidentApr 16Sale242.2210,0002,422,166470,174Apr 17 09:00 PM
Pruzanski MarkCEO & PresidentApr 15Option Exercise6.1730,309186,926470,174Apr 17 09:00 PM
TALLARIGO LORENZODirectorApr 10Sale293.9130,6239,000,4066,454,953Apr 11 09:01 PM
Genextra S.p.A.10% OwnerApr 10Sale293.9130,6239,000,4066,454,953Apr 11 09:02 PM
Micheli Francesco10% OwnerApr 10Sale293.9130,6239,000,4066,454,953Apr 11 09:03 PM
Micheli Francesco10% OwnerApr 09Sale320.00318,695101,982,4005,620,195Apr 11 09:03 PM
Genextra S.p.A.10% OwnerApr 09Sale320.00318,695101,982,4005,620,195Apr 11 09:02 PM
ORBIMED ADVISORS LLCDirectorApr 09Sale320.0081,30526,017,6001,654,603Apr 11 05:27 PM
TALLARIGO LORENZODirectorApr 09Sale320.00318,695101,982,4005,620,195Apr 11 09:01 PM
SILVERSTEIN JONATHANDirectorApr 09Sale320.0081,30526,017,6001,653,629Apr 11 09:00 PM
Adorini LucianoChief Scientific OfficerApr 07Option Exercise10.402,00020,8009,041Apr 09 09:00 PM
Adorini LucianoChief Scientific OfficerApr 07Sale283.902,000567,8007,041Apr 09 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentApr 02Sale321.95879282,99713,679Apr 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentApr 01Option Exercise10.404,32644,99119,072Apr 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentApr 01Sale333.764,5141,506,58814,558Apr 03 09:01 PM
Shapiro DavidCMO and EVP - DevelopmentMar 17Option Exercise10.408,91792,73817,580Mar 19 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentMar 17Sale437.494,4561,949,45013,124Mar 19 09:00 PM
Adorini LucianoChief Scientific OfficerMar 07Option Exercise10.402,00020,8008,392Mar 11 09:00 PM
Adorini LucianoChief Scientific OfficerMar 07Sale421.312,000842,6206,392Mar 11 09:00 PM
Regan Daniel PaulChief Commercial OfficerMar 05Option Exercise37.6920,000753,80020,000Mar 07 09:00 PM
Regan Daniel PaulChief Commercial OfficerMar 05Sale434.6920,0008,693,8210Mar 07 09:00 PM
Shapiro DavidCMO and EVP - DevelopmentFeb 14Option Exercise10.404,32745,00112,990Feb 18 09:46 PM
Shapiro DavidCMO and EVP - DevelopmentFeb 14Sale367.115,7722,118,9477,218Feb 18 09:46 PM
Fundaro PaoloDirectorFeb 14Sale367.51324119,0731,655Feb 14 09:00 PM
Fundaro PaoloDirectorFeb 12Option Exercise8.676,92259,9918,901Feb 14 09:00 PM
Fundaro PaoloDirectorFeb 12Sale375.626,9222,600,0291,979Feb 14 09:00 PM
VEITINGER KLAUS R DRDirectorFeb 10Sale377.7216261,1902,282Feb 11 09:02 PM
TALLARIGO LORENZODirectorFeb 10Sale354.52368130,4631,640Feb 11 09:02 PM
Adorini LucianoChief Scientific OfficerFeb 07Option Exercise10.402,00020,8008,392Feb 11 09:00 PM
Adorini LucianoChief Scientific OfficerFeb 07Sale305.152,000610,3006,392Feb 11 09:00 PM
Pruzanski MarkPresident and CEOJan 16Option Exercise8.6710,00086,667440,298Jan 17 09:00 PM
AKKARAJU SRINIVASDirectorJan 16Option Exercise21.502,50053,7505,193Jan 17 09:01 PM
AKKARAJU SRINIVASDirectorJan 16Sale267.943,250870,8051,943Jan 17 09:01 PM
Pruzanski MarkPresident and CEOJan 16Sale273.6810,0002,736,767430,298Jan 17 09:00 PM
Duncan Barbara GayleChief Financial OfficerJan 15Option Exercise31.905,625179,43816,333Jan 17 09:01 PM
Duncan Barbara GayleChief Financial OfficerJan 15Sale259.185,6251,457,91510,708Jan 17 09:01 PM
Pruzanski MarkPresident and CEODec 30Option Exercise2.8921,50362,120438,138Jan 17 09:00 PM